| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Physiology and Biophysics, and Chemistry, University of Illinois and University of Illinois College of Medicine Urbana, Illinois 61801
Address all correspondence and requests for reprints to: Dr. Benita S. Katzenellenbogen, Department of Physiology and Biophysics, 524 Burrill Hall, University of Illinois, 407 South Goodwin Avenue, Urbana, Illinois 61801.
Abstract
We have used a covalently attaching antiestrogen, tamoxifen aziridine [TA; (Z)-(l-[4-(2-[N-aziridinyl] ethoxy)phenyl])l,2-diphenyl-l-butene], to analyze the structure and dynamics of the estrogen receptor in MCF-7 human breast cancer cells. The labeling of receptor with [3H]TA is specific, being blocked only by estrogens and antiestrogens, and the labeling is very efficient in that TA labels covalently the same number of receptors that are labeled reversibly by estradiol. In cells exposed to[3H]TA for 1 h, most of the covalently associated radioactivity is found in the 0.6 M KC1 extract of the nuclear fraction; this receptor has an apparent mol wt of 63,000 ± 2000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a pi of 5.7 by gel isoelectric focusing in the presence of 8 M urea. The mol wt and pi of cytosol receptor labeled with [3H] TA are identical. In cells labeled with [3H]TA (20 nM) for 1 h and then exposed to a chase of 10–6 M estradiol, [3H]TA-labeled nuclear receptor disappears with a half-life of 4 h. Analysis ofnuclear receptor by sodium dodecyl sulfate-gels during the chase period reveals that this loss reflects a decrease in the 63,000 mol wt species; no significant quantities of lower mol wt TA-labeled fragments are observed in the nuclear, cytosol, or membrane fractions. Affinity labeled receptor interacts with several monoclonal antibodies to MCF-7 estrogen receptor, and it can be purified extensively by immunoadsorbent chromatography. TA has a low affinity (8% that of tamoxifen) for microsomal antiestrogen- binding sites that are distinct from the estrogen receptor, but TA reacts reversibly, rather than covalently, with these sites. The findings of similar mol wt and isoelectric points for soluble cytosol and nuclear extracted receptors under strongly denaturing and disaggregating conditions reveal that nuclear localization of receptor after ligand binding is not associated with major structural alterations in the receptor component labeled by TA. In addition, the receptor, even when occupied by a covalently attached ligand, is rapidly turned over in these cells. (Endocrinology 115: 143–153, 1984)
Footnotes
* This work was supported by NIH Grants CA-18119 and CA-31870 to B.S.K.) and AM-15556 (to J.A.K.). A preliminary report of portions of this work was presented at the 65th Annual Meeting of The Endocrine Society, June 1983, and is listed as Ref. 51.
Received November 29, 1983.
This article has been cited by other articles:
![]() |
N. B. Berry, M. Fan, and K. P. Nephew Estrogen Receptor-{alpha} Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome Mol. Endocrinol., July 1, 2008; 22(7): 1535 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C Valley, N. M Solodin, G. L Powers, S. J Ellison, and E. T Alarid Temporal variation in estrogen receptor-{alpha} protein turnover in the presence of estrogen J. Mol. Endocrinol., January 1, 2008; 40(1): 23 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Schultz-Norton, V. A. Gabisi, Y. S. Ziegler, I. X. McLeod, J. R. Yates, and A. M. Nardulli Interaction of estrogen receptor {alpha} with proliferating cell nuclear antigen Nucleic Acids Res., August 1, 2007; 35(15): 5028 - 5038. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Harrington, S. Sengupta, and B. S. Katzenellenbogen Estrogen Regulation of the Glucuronidation Enzyme UGT2B15 in Estrogen Receptor-Positive Breast Cancer Cells Endocrinology, August 1, 2006; 147(8): 3843 - 3850. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Alarid, N. Bakopoulos, and N. Solodin Proteasome-Mediated Proteolysis of Estrogen Receptor: A Novel Component in Autologous Down-Regulation Mol. Endocrinol., September 1, 1999; 13(9): 1522 - 1534. [Abstract] [Full Text] |
||||
![]() |
B. S. Katzenellenbogen and K. S. Korach Editorial: A New Actor in the Estrogen Receptor Drama--Enter ER-{beta} Endocrinology, March 1, 1997; 138(3): 861 - 862. [Full Text] [PDF] |
||||
![]() |
A. L. Wijayaratne and D. P. McDonnell The Human Estrogen Receptor-alpha Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators J. Biol. Chem., September 14, 2001; 276(38): 35684 - 35692. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Preisler-Mashek, N. Solodin, B. L. Stark, M. K. Tyriver, and E. T. Alarid Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E891 - E898. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |